Lena Dunn
Family · Pensacola, FLNPI 1083126692
Payments from drug & device makers
Across 190 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$975
- Dexcom, Inc.$389
- Lilly USA, LLC$276
- Gilead$275
- Novo Nordisk$273
- Novartis$259
- plus $999 from 19 others
What the payments were for
- Food & beverage$3,447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $975 |
| Dexcom, Inc. | 10 | $389 |
| Lilly USA, LLC | 19 | $276 |
| Gilead | 11 | $275 |
| Novo Nordisk | 16 | $273 |
| Novartis | 14 | $259 |
| AstraZeneca | 8 | $219 |
| GSK | 10 | $147 |
| Bayer | 7 | $124 |
| Pfizer | 7 | $117 |
| Exact Sciences | 5 | $80 |
| Amgen | 4 | $56 |
| Astellas Pharma US Inc | 2 | $44 |
| Indivior Inc. | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Mckesson Medical-surgical, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Abbott | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
How this compares
$3,447 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $120,152 |
| MounjaroTirzepatide | 60 | $86,376 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $85,070 |
| FarxigaDapagliflozin Propanediol | 73 | $77,681 |
| EliquisApixaban | 31 | $32,843 |
| RybelsusSemaglutide | 11 | $28,506 |
| JardianceEmpagliflozin | 21 | $28,446 |
| JanuviaSitagliptin Phosphate | 15 | $22,697 |
| TrulicityDulaglutide | 11 | $17,302 |
| MyrbetriqMirabegron | 17 | $15,540 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $14,245 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 16 | $13,948 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $13,546 |
| Spiriva RespimatTiotropium Bromide | 13 | $10,105 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $7,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $273 | $148,65896 claims |
| Lilly USA, LLCMounjaro, Trulicity | $276 | $103,67871 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $147 | $98,61778 claims |
| AstraZenecaFarxiga, Symbicort | $219 | $85,544107 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $17 | $38,55134 claims |
| PfizerEliquis | $117 | $32,84331 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $15,54017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Pensacola
- Brittany PerezPensacola$130K
- Mary AanestadPensacola$54K
- Raymond HalsteadPensacola$50K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.